Cargando…

Construction of immune‐related risk signature for renal papillary cell carcinoma

The kidney renal papillary cell carcinoma (KIRP) is a relatively rare type of kidney cancer. There has been no investigation to find a robust signature to predict the survival outcome of KIRP patients in the aspect of tumor immunology. In this study, 285 KIRP samples from The Cancer Genome Atlas (TC...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhongyu, Song, Qian, Yang, Zuyi, Chen, Jianing, Shang, Jun, Ju, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346237/
https://www.ncbi.nlm.nih.gov/pubmed/30516029
http://dx.doi.org/10.1002/cam4.1905
_version_ 1783389724534112256
author Wang, Zhongyu
Song, Qian
Yang, Zuyi
Chen, Jianing
Shang, Jun
Ju, Wen
author_facet Wang, Zhongyu
Song, Qian
Yang, Zuyi
Chen, Jianing
Shang, Jun
Ju, Wen
author_sort Wang, Zhongyu
collection PubMed
description The kidney renal papillary cell carcinoma (KIRP) is a relatively rare type of kidney cancer. There has been no investigation to find a robust signature to predict the survival outcome of KIRP patients in the aspect of tumor immunology. In this study, 285 KIRP samples from The Cancer Genome Atlas (TCGA) were randomly divided into training and testing set. A total of 1534 immune‐related genes from The Immunology Database and Analysis Portal (ImmPort) were used as candidates to construct the signature. Using univariate Cox analysis, we evaluated the relationship between overall survival and immune‐related genes expression and found 272 immune‐related genes with predicting prognostic ability. In order to construct an efficient predictive model, the Cox proportional hazards model with an elastic‐net penalty was used and identified 23 groups after 1000 iterations. As a result, 15‐genes model showing more stable than other gene groups was chosen to construct our immune‐related risk signature. In line with our expectations, the signature can independently predict the survival outcome of KIRP patients. Patients with high‐immune risk were found correlated with advanced stage. We also found that the high‐immune risk patients with higher PBRM1 and SETD2 mutations, increasing chromosomal instability, together with the gene set enrichment analysis (GSEA) results showing intensive connection of our signature with immune pathways. In conclusion, our study constructs a robust 15‐gene signature for predicting KIRP patients’ survival outcome on the basis of tumor immune environment and may provide possible relationship between prognosis and immune‐related biological function.
format Online
Article
Text
id pubmed-6346237
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63462372019-01-29 Construction of immune‐related risk signature for renal papillary cell carcinoma Wang, Zhongyu Song, Qian Yang, Zuyi Chen, Jianing Shang, Jun Ju, Wen Cancer Med Cancer Biology The kidney renal papillary cell carcinoma (KIRP) is a relatively rare type of kidney cancer. There has been no investigation to find a robust signature to predict the survival outcome of KIRP patients in the aspect of tumor immunology. In this study, 285 KIRP samples from The Cancer Genome Atlas (TCGA) were randomly divided into training and testing set. A total of 1534 immune‐related genes from The Immunology Database and Analysis Portal (ImmPort) were used as candidates to construct the signature. Using univariate Cox analysis, we evaluated the relationship between overall survival and immune‐related genes expression and found 272 immune‐related genes with predicting prognostic ability. In order to construct an efficient predictive model, the Cox proportional hazards model with an elastic‐net penalty was used and identified 23 groups after 1000 iterations. As a result, 15‐genes model showing more stable than other gene groups was chosen to construct our immune‐related risk signature. In line with our expectations, the signature can independently predict the survival outcome of KIRP patients. Patients with high‐immune risk were found correlated with advanced stage. We also found that the high‐immune risk patients with higher PBRM1 and SETD2 mutations, increasing chromosomal instability, together with the gene set enrichment analysis (GSEA) results showing intensive connection of our signature with immune pathways. In conclusion, our study constructs a robust 15‐gene signature for predicting KIRP patients’ survival outcome on the basis of tumor immune environment and may provide possible relationship between prognosis and immune‐related biological function. John Wiley and Sons Inc. 2018-12-05 /pmc/articles/PMC6346237/ /pubmed/30516029 http://dx.doi.org/10.1002/cam4.1905 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Biology
Wang, Zhongyu
Song, Qian
Yang, Zuyi
Chen, Jianing
Shang, Jun
Ju, Wen
Construction of immune‐related risk signature for renal papillary cell carcinoma
title Construction of immune‐related risk signature for renal papillary cell carcinoma
title_full Construction of immune‐related risk signature for renal papillary cell carcinoma
title_fullStr Construction of immune‐related risk signature for renal papillary cell carcinoma
title_full_unstemmed Construction of immune‐related risk signature for renal papillary cell carcinoma
title_short Construction of immune‐related risk signature for renal papillary cell carcinoma
title_sort construction of immune‐related risk signature for renal papillary cell carcinoma
topic Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346237/
https://www.ncbi.nlm.nih.gov/pubmed/30516029
http://dx.doi.org/10.1002/cam4.1905
work_keys_str_mv AT wangzhongyu constructionofimmunerelatedrisksignatureforrenalpapillarycellcarcinoma
AT songqian constructionofimmunerelatedrisksignatureforrenalpapillarycellcarcinoma
AT yangzuyi constructionofimmunerelatedrisksignatureforrenalpapillarycellcarcinoma
AT chenjianing constructionofimmunerelatedrisksignatureforrenalpapillarycellcarcinoma
AT shangjun constructionofimmunerelatedrisksignatureforrenalpapillarycellcarcinoma
AT juwen constructionofimmunerelatedrisksignatureforrenalpapillarycellcarcinoma